The new European Union Clinical Trial Regulation (EU No. 536/2014) is designed to make the European Union a more attractive location for clinical research. It will, however, require changes in the way that pharmaceutical and device companies handle clinical trials for clinical research sites located in the European Union. In order to help prepare sponsors and investigators for the new regulation, this article provides an overview of the current system and the changes under the new clinical trial regulation.